Kenvue Inc. (NYSE:KVUE) Short Interest Update

Kenvue Inc. (NYSE:KVUE - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 37,630,000 shares, an increase of 18.9% from the February 13th total of 31,660,000 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average trading volume of 13,950,000 shares, the days-to-cover ratio is currently 2.7 days.

Kenvue Trading Down 0.2 %

Shares of NYSE:KVUE traded down $0.05 during trading hours on Friday, hitting $23.34. 35,334,673 shares of the company's stock traded hands, compared to its average volume of 16,169,860. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The business has a fifty day moving average price of $22.08 and a 200-day moving average price of $22.43. The firm has a market capitalization of $44.61 billion, a P/E ratio of 44.04, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Remove Ads

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KVUE. Norges Bank purchased a new stake in shares of Kenvue in the fourth quarter valued at approximately $521,348,000. Starboard Value LP purchased a new stake in shares of Kenvue in the fourth quarter valued at approximately $467,864,000. State Street Corp boosted its holdings in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KVUE. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a report on Friday, January 17th. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and reduced their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Finally, Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.